[
  {
    "input": "What is PADCEV used for?",
    "expected_output": "PADCEV is used for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have received one or more prior lines of therapy.",
    "context": "PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who:\n• have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or\n• are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. (Section 1, Indications and Usage)"
  },
  {
    "input": "What are the most common side effects of PADCEV?",
    "expected_output": "The most common side effects (≥20%) include rash, increased liver enzymes (AST, ALT), high blood sugar, increased creatinine, fatigue, peripheral neuropathy, decreased lymphocytes, hair loss, decreased appetite, low hemoglobin, diarrhea, low sodium, nausea, itching, low phosphate, altered taste, anemia, low albumin, low neutrophils, increased uric acid, increased lipase, low platelets, weight loss, and dry skin.",
    "context": "The most common adverse reactions, including laboratory abnormalities (≥20%), included rash, aspartate aminotransferase increased, glucose increased, creatinine increased, fatigue, peripheral neuropathy, lymphocytes decreased, alopecia, decreased appetite, hemoglobin decreased, diarrhea, sodium decreased, nausea, pruritus, phosphate decreased, dysgeusia, alanine aminotransferase increased, anemia, albumin decreased, neutrophils decreased, urate increased, lipase increased, platelets decreased, weight decreased, and dry skin. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "What are the serious warnings associated with PADCEV?",
    "expected_output": "PADCEV has serious warnings, including severe and potentially fatal skin reactions (SJS/TEN), hyperglycemia that can lead to diabetic ketoacidosis, life-threatening pneumonitis, peripheral neuropathy, vision changes, infusion site reactions, and fetal harm if used during pregnancy.",
    "context": "PADCEV can cause severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). It may also lead to diabetic ketoacidosis, severe pneumonitis, and peripheral neuropathy. Ocular disorders, including vision changes, have been reported. Infusion site extravasation reactions and embryo-fetal toxicity are also concerns. (Sections 5.1-5.7, Warnings and Precautions)"
  },
  {
    "input": "How is PADCEV administered?",
    "expected_output": "PADCEV is given as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28-day cycle. The recommended dose is 1.25 mg/kg (up to 125 mg per dose).",
    "context": "The recommended dose of PADCEV is 1.25 mg/kg (up to a maximum dose of 125 mg for patients ≥100 kg) administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. (Section 2.1, Dosage and Administration)"
  },
  {
    "input": "What should I do if I experience a severe skin reaction while on PADCEV?",
    "expected_output": "Stop taking PADCEV immediately and seek medical attention if you develop a severe skin reaction, including rash, blistering, or peeling skin, as these may indicate Stevens-Johnson syndrome or toxic epidermal necrolysis.",
    "context": "PADCEV can cause severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). If suspected, immediately withhold PADCEV and consider referral for specialized care. Permanently discontinue PADCEV if confirmed. (Section 5.1, Warnings and Precautions)"
  },
  {
    "input": "Can PADCEV be used during pregnancy?",
    "expected_output": "PADCEV can cause fetal harm and should not be used during pregnancy. Women should use effective contraception during treatment and for at least 2 months after the last dose. Men with female partners should use contraception for at least 4 months after the last dose.",
    "context": "Based on its mechanism of action and findings in animals, PADCEV can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment and for 2 months after the last dose. Male patients should use contraception for 4 months after the last dose. (Section 8.1, Pregnancy)"
  },
  {
    "input": "What precautions should diabetics take when using PADCEV?",
    "expected_output": "Patients with diabetes or those at risk should have their blood sugar closely monitored. If blood glucose levels exceed 250 mg/dL, PADCEV should be withheld until glucose levels improve.",
    "context": "Hyperglycemia, including diabetic ketoacidosis, may occur in patients with or without preexisting diabetes. Patients should have blood glucose levels monitored closely, and PADCEV should be withheld if blood glucose is >250 mg/dL. (Section 5.2, Hyperglycemia)"
  },
  {
    "input": "What should I do if I experience numbness or tingling while on PADCEV?",
    "expected_output": "Inform your doctor immediately if you experience numbness, tingling, or muscle weakness, as PADCEV can cause peripheral neuropathy. Your doctor may adjust your dose or stop treatment.",
    "context": "Peripheral neuropathy occurred in 52% of patients treated with PADCEV. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or reduction if needed. (Section 5.4, Peripheral Neuropathy)"
  },
  {
    "input": "Can I breastfeed while taking PADCEV?",
    "expected_output": "No, women should not breastfeed while taking PADCEV and for at least 3 weeks after the last dose due to potential risks to the baby.",
    "context": "There are no data on the presence of enfortumab vedotin-ejfv in human milk, but due to the potential for serious adverse reactions in a breastfed child, women should not breastfeed during treatment and for at least 3 weeks after the last dose. (Section 8.2, Lactation)"
  },
  {
    "input": "Can PADCEV be used in patients with liver disease?",
    "expected_output": "PADCEV should be avoided in patients with moderate or severe liver impairment due to the increased risk of adverse reactions.",
    "context": "Avoid the use of PADCEV in patients with moderate or severe hepatic impairment (total bilirubin >1.5 x ULN and AST any). Patients with moderate hepatic impairment showed increased risk of adverse effects. (Section 8.6, Hepatic Impairment)"
  },
    {
    "input": "What should I do if I experience severe fatigue while on PADCEV?",
    "expected_output": "Fatigue is a common side effect of PADCEV, occurring in up to 56% of patients. If fatigue becomes severe or persistent, consult your doctor, as dose modification may be necessary.",
    "context": "Fatigue was reported in 56% of patients in clinical trials. Patients experiencing Grade 3 or higher fatigue should have their dose withheld until symptoms resolve. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "Does PADCEV affect kidney function?",
    "expected_output": "Yes, PADCEV can lead to increased creatinine levels and acute kidney injury in some patients. If you experience symptoms such as decreased urine output or swelling, consult your doctor immediately.",
    "context": "PADCEV may cause renal toxicity, including increased creatinine levels. In clinical trials, acute kidney injury occurred in 7% of patients. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "Can PADCEV cause weight loss?",
    "expected_output": "Yes, weight loss is a potential side effect of PADCEV, occurring in approximately 35% of patients. If significant weight loss occurs, consult your doctor.",
    "context": "Weight loss was reported in 35% of patients treated with PADCEV. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "What should I do if I experience eye problems while taking PADCEV?",
    "expected_output": "PADCEV can cause dry eyes and vision changes. If you experience blurred vision, eye irritation, or excessive tearing, consult your doctor. Use artificial tears for dry eyes.",
    "context": "Ocular disorders, including dry eye (40%) and blurred vision (13%), have been reported. Artificial tears and ophthalmic steroids may be recommended. (Section 5.5, Ocular Disorders)"
  },
  {
    "input": "Is PADCEV safe for older adults?",
    "expected_output": "Yes, PADCEV has been studied in older adults. In clinical trials, 65% of patients were aged 65 or older, and no significant differences in safety were observed compared to younger patients.",
    "context": "Of the 680 patients treated in clinical trials, 65% were 65 years or older, and 25% were 75 years or older. No overall differences in safety or effectiveness were observed. (Section 8.5, Geriatric Use)"
  },
  {
    "input": "Can PADCEV cause anemia?",
    "expected_output": "Yes, PADCEV may cause anemia, which was reported in 34% of patients. If you experience dizziness, shortness of breath, or pale skin, consult your doctor.",
    "context": "Anemia was reported in 34% of patients in clinical trials, with 10% experiencing Grade 3 or 4 severity. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "What are the risks of PADCEV for people with liver problems?",
    "expected_output": "PADCEV should be avoided in patients with moderate or severe liver impairment due to the increased risk of adverse effects.",
    "context": "PADCEV is not recommended for patients with moderate or severe hepatic impairment due to increased drug exposure and risk of toxicity. (Section 8.6, Hepatic Impairment)"
  },
  {
    "input": "What should I do if I develop a cough while taking PADCEV?",
    "expected_output": "A persistent or worsening cough may be a sign of pneumonitis. Inform your doctor immediately if you develop a cough, shortness of breath, or fever.",
    "context": "Pneumonitis, including life-threatening cases, has been reported with PADCEV. Monitor for symptoms such as cough or difficulty breathing. (Section 5.3, Pneumonitis)"
  },
  {
    "input": "Can PADCEV cause high blood sugar?",
    "expected_output": "Yes, PADCEV can cause hyperglycemia. If you have diabetes or are at risk, your blood sugar should be closely monitored. If your blood glucose exceeds 250 mg/dL, PADCEV should be temporarily withheld.",
    "context": "Hyperglycemia, including diabetic ketoacidosis, has been observed in patients treated with PADCEV. Blood glucose levels should be monitored closely. (Section 5.2, Hyperglycemia)"
  },
  {
    "input": "How does PADCEV work?",
    "expected_output": "PADCEV is an antibody-drug conjugate targeting Nectin-4, a protein found on cancer cells. It delivers a toxic agent that disrupts the cancer cell's microtubule network, leading to cell death.",
    "context": "PADCEV is a Nectin-4-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), a microtubule-disrupting agent, to cancer cells, leading to their destruction. (Section 12.1, Mechanism of Action)"
  },
  {
    "input": "Can PADCEV interact with other medications?",
    "expected_output": "Yes, PADCEV may interact with certain drugs, especially strong CYP3A4 inhibitors and P-gp inhibitors, which can increase drug exposure and toxicity. Inform your doctor about all medications you are taking.",
    "context": "PADCEV exposure may be increased when used with strong CYP3A4 inhibitors and P-gp inhibitors, potentially leading to increased toxicity. (Section 7.1, Drug Interactions)"
  },
  {
    "input": "What should I do if I experience infusion site reactions?",
    "expected_output": "If you experience redness, swelling, or pain at the infusion site, notify your healthcare provider immediately. In severe cases, treatment may need to be stopped.",
    "context": "Infusion site extravasation has been observed. If extravasation occurs, the infusion should be stopped, and the site should be monitored for worsening symptoms. (Section 5.6, Infusion Site Extravasation)"
  },
  {
    "input": "Can PADCEV cause nausea or vomiting?",
    "expected_output": "Yes, PADCEV can cause nausea (30%) and vomiting (18%). If these symptoms persist or become severe, anti-nausea medication may be needed.",
    "context": "Nausea was reported in 30% of patients, and vomiting in 18%. Patients experiencing severe nausea should consult their doctor for symptom management. (Section 6.1, Adverse Reactions)"
  },
  {
    "input": "Can PADCEV affect fertility?",
    "expected_output": "PADCEV may impair male fertility. Men should consider sperm preservation before starting treatment.",
    "context": "Animal studies suggest PADCEV may cause male fertility impairment. Men should be advised about potential risks before treatment. (Section 13.1, Carcinogenesis, Mutagenesis, Impairment of Fertility)"
  },
   {
    "input": "Can PADCEV affect my blood cell counts?",
    "expected_output": "Yes, PADCEV can lower white blood cells, red blood cells, and platelet counts. This may increase the risk of infections, anemia, or bleeding. Your doctor may monitor your blood counts regularly.",
    "context": "PADCEV may cause decreases in lymphocytes (43%), hemoglobin (34%), and neutrophils (20%), increasing the risk of infections, anemia, and bleeding. (Section 6.1, Clinical Trials Experience)&#8203;:contentReference[oaicite:0]{index=0}"
  },
  {
    "input": "Can PADCEV cause heart-related side effects?",
    "expected_output": "PADCEV has not been directly linked to major heart conditions, but side effects such as anemia, dehydration, or electrolyte imbalances could potentially impact heart function.",
    "context": "No direct cardiovascular toxicities have been observed, but anemia (34%), sodium decrease (7%), and potassium decrease (8%) may contribute to cardiovascular risks. (Section 6.1, Adverse Reactions)&#8203;:contentReference[oaicite:1]{index=1}"
  },
  {
    "input": "How does PADCEV affect digestion?",
    "expected_output": "PADCEV can cause nausea, diarrhea, decreased appetite, and abdominal pain. If these symptoms persist, your doctor may adjust your treatment.",
    "context": "Gastrointestinal side effects include diarrhea (42%), nausea (30%), decreased appetite (52%), and abdominal pain (20%). (Table 5, Adverse Reactions)&#8203;:contentReference[oaicite:2]{index=2}"
  },
  {
    "input": "Does PADCEV affect nerve function?",
    "expected_output": "Yes, PADCEV can cause peripheral neuropathy, leading to numbness, tingling, or muscle weakness. Notify your doctor if you develop these symptoms.",
    "context": "Peripheral neuropathy occurred in 56% of patients, including sensory neuropathy (39%) and motor neuropathy (6%). (Section 5.4, Peripheral Neuropathy)&#8203;:contentReference[oaicite:3]{index=3}"
  },
  {
    "input": "Can PADCEV lead to high blood pressure?",
    "expected_output": "PADCEV has not been strongly associated with high blood pressure, but it can cause dehydration and electrolyte imbalances, which may affect blood pressure.",
    "context": "PADCEV can cause dehydration, sodium imbalance (7%), and potassium imbalance (8%), which may influence blood pressure regulation. (Section 6.1, Laboratory Abnormalities)&#8203;:contentReference[oaicite:4]{index=4}"
  },
  {
    "input": "Does PADCEV affect the immune system?",
    "expected_output": "Yes, PADCEV can lower white blood cell counts, increasing the risk of infections. Your doctor may monitor your immune function during treatment.",
    "context": "PADCEV treatment resulted in decreased lymphocyte counts in 43% of patients, which may weaken immune responses. (Section 6.1, Laboratory Abnormalities)&#8203;:contentReference[oaicite:5]{index=5}"
  },
  {
    "input": "Can PADCEV cause bleeding problems?",
    "expected_output": "Yes, PADCEV may reduce platelet counts, increasing the risk of bleeding. Inform your doctor if you experience unusual bruising or bleeding.",
    "context": "Platelet count decreases were observed in patients treated with PADCEV, which may lead to an increased risk of bleeding. (Section 6.1, Laboratory Abnormalities)&#8203;:contentReference[oaicite:6]{index=6}"
  },
  {
    "input": "Can PADCEV cause dehydration?",
    "expected_output": "Yes, PADCEV may cause diarrhea, vomiting, or decreased appetite, which can lead to dehydration. It is important to stay well-hydrated.",
    "context": "Common side effects include diarrhea (42%), nausea (30%), and decreased appetite (52%), which can contribute to dehydration. (Section 6.1, Adverse Reactions)&#8203;:contentReference[oaicite:7]{index=7}"
  },
  {
    "input": "Can PADCEV cause serious infections?",
    "expected_output": "Yes, PADCEV can lower white blood cell counts, increasing the risk of infections. Some patients have developed pneumonia and sepsis.",
    "context": "Serious infections, including pneumonia and sepsis (5% each), have been reported in patients receiving PADCEV. (Section 6.1, Clinical Trials Experience)&#8203;:contentReference[oaicite:8]{index=8}"
  },
  {
    "input": "Can PADCEV cause muscle pain?",
    "expected_output": "Yes, muscle pain and weakness have been reported as side effects. If you experience severe or worsening symptoms, notify your doctor.",
    "context": "Musculoskeletal pain was observed in 25% of patients, including muscle stiffness and weakness. (Table 5, Adverse Reactions)&#8203;:contentReference[oaicite:9]{index=9}"
  }
]

